So-Young International Inc.

NASDAQ:SY

Medical - Healthcare Information Services

Healthcare
$1.83 -5.83%

-$0.09 today

Market cap
$239.36M
Beta
1.98
P/E (TTM)
-5.0
EPS (TTM)
-$1.95
52W Low $1.00High $6.28

Volume 0.46M

Average 0.63M

SY Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

So-Young International Inc.NASDAQ: SY

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of CN¥24.19M fell 24.7% year over year, behind the -18.4% change in trailing-twelve-month research & development. Sequentially, it fell 34.5% from the prior quarter. Over 3 fiscal years it compounded at -17.2% a year.

Context

  • Research & development amounted to 9.0% of revenue in FY2025, down 2.3 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -24.7% toward the trailing-twelve-month pace of -18.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CN¥24.19M-34.5% QoQ
Last fiscal yearDec 2025
CN¥133.31M-19.2% YoY
LTMMar 2026
CN¥128.61M-18.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-24.7%——
1 year-19.2%——
3-year CAGR-17.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

CNY · from the income statement

Latest · FY2025
133.31M CNY
Year-over-year change
-19.2%
4-year CAGR
-17.4%

Research & Development vs competitors

How SY compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -18.4% is the 6th highest of 10, against a peer median of -15.8%.
  • Research & development amounts to 7.8% of revenue for SY, versus a peer median of 35.1%.
SY Competitors
Research & Development for SY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$188.07M USD+22.3%+26.8%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$162.51M USD-21.6%+18.9%—
SYSo-Young International Inc.LTM Mar 2026CN¥128.61M CNY-18.4%-17.2%7.8%
ADCTADC Therapeutics S.A.LTM Mar 2026$94.95M USD-15.8%-17.7%119.9%
VREXVarex Imaging CorporationLTM Apr 2026$89.5M USD+0.1%+5.8%10.4%
OMEROmeros CorporationLTM Mar 2026$70.57M USD-39.3%-10.3%713.3%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$58.28M USD-31.8%+5.0%83.7%
SOPHSOPHiA GENETICS S.A.LTM Mar 2026$35.89M USD+5.3%-1.7%44.2%
LABStandard BioTools Inc.LTM Mar 2026$22.48M USD-43.6%-11.4%26.1%
SLPSimulations Plus, Inc.LTM Feb 2026$9.34M USD+29.5%+29.0%11.6%
SNDASonida Senior Living, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding SY) —-15.8%+5.0%35.1%

Competitors are the stored peer set for SY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.69B1.26B1.5B1.47B1.48B
Cost of Revenue327.89M393.29M544.34M567.59M774.04M
Gross Profit1.36B864.58M953.69M899.11M707.86M
Gross Margin80.6%68.7%63.7%61.3%47.8%
Research & Development286.57M235.09M203.52M165.03M133.31M
Selling, General & Admin1.04B732.3M811.22M818.57M833.76M
Operating Expenses1.4B967.39M1.01B1.52B967.07M
Depreciation & Amortization30.08M47.09M46.09M46.09M57.21M
EBITDA63.39M(39.99M)53.96M(38.39M)(182.19M)
EBITDA Margin3.7%-3.2%3.6%-2.6%-12.3%
Operating Income(32.57M)(102.81M)(61.05M)(624.49M)(259.21M)
Operating Margin-1.9%-8.2%-4.1%-42.6%-17.5%
Interest Income19.33M28.88M48.84M46.51M24.6M
Interest Expense00000
Other Income / Expenses16.17M15.73M68.92M36.41M19.8M
Income Before Tax(16.41M)(87.07M)7.87M(588.09M)(239.4M)
Pre-Tax Margin-1.0%-6.9%0.5%-40.1%-16.2%
Income Tax Expense21.23M(20.97M)(18.08M)(905K)(774.31K)
Net Income(8.37M)(65.55M)21.28M(589.53M)(235.7M)
Net Margin-0.5%-5.2%1.4%-40.2%-15.9%
EPS (Basic)(0.06)(0.48)0.16(4.40)(1.78)
EPS (Diluted)(0.06)(0.48)0.16(4.39)(1.78)
Weighted Avg Shares138.04M138.04M133.19M134.09M131.59M
Weighted Avg Shares (Diluted)138.04M138.04M131.91M134.16M131.59M

So-Young International Inc.

NASDAQ:SY

Intrinsic Alpha fair value

Locked

Current Price

$1.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.